Table 1.

Summary of patient characteristics across WHO 2017 WBC count–based subtypes, MDS- and MP-CMML

VariableMDS-CMMLMP-CMMLP*
Patients, N (%) 306 (48.6) 323 (51.4)  
Age, median (range), y 69.9 (31.2-91.1) 69.9 (24.8-87.6) .9559 
Age group, n (%), y    
 <60 61 (19.9) 55 (17.0) .4987 
 60-69 152 (49.7) 158 (48.9)  
 ≥70 93 (30.4) 110 (34.1)  
Sex, n (%)    
 Female 93 (30.4) 106 (32.8) .5133 
 Male 213 (69.6) 217 (67.2)  
WHO-2017, n (%)    
 CMML-0 122 (39.9) 92 (28.5) .0052 
 CMML-1 101 (33.0) 113 (35.0)  
 CMML-2 83 (27.1) 118 (36.5)  
WHO-2008, n (%)    
 CMML-1 223 (72.9) 205 (63.5) .0114 
 CMML-2 83 (27.1) 118 (36.5)  
PB parameters    
 WBC count, median (range), ×109/L 7.3 (0.8-12.9) 28.7 (13.0-223.1) <.0001 
 Hemoglobin concentration, median (range), g/dL 10.6 (5.9-16.0) 10.2 (5.1-16.4) .0905 
 Platelet count, median (range), ×109/L 88.5 (2.0-1554) 94.0 (5.0-912.0) .2705 
 Immature myeloid cells, median (minimum-maximum) 1.0 (0.0-34.0) 8.0 (0.0-50.0) <.0001 
 LDH, median (range), IU/L 537.0 (191-3400) 749.0 (142-11060) <.0001 
BM blast percentage, median (range) 5.5 (0.0-19.0) 6.0 (0.0-19.0) .7885 
MDAPS group, n (%)    
 High 47 (15.4) 57 (17.6) <.0001 
 Intermediate-2 98 (32.0) 186 (57.6)  
 Intermediate-1 110 (35.9) 66 (20.4)  
 Low 51 (16.7) 14 (4.3)  
CPSS group, n (%)    
 HIGH 16 (5.2) 49 (15.2) <.0001 
 INT-2 85 (27.8) 178 (55.1)  
 INT-1 90 (29.4) 96 (29.7)  
 Low 115 (37.6) 0 (0)  
CPSS cytogenetic risk groups, n (%) 
 High 58 (19.0) 50 (15.5) .0704 
 Intermediate 36 (11.8) 58 (18.0)  
 Low 212 (69.3) 215 (66.6)  
Tang cytogenetic risk groups, n (%) 
 High 36 (11.8) 36 (11.1) .5856 
 Intermediate 58 (19.0) 72 (22.3)  
 Low 212 (69.3) 215 (66.6)  
Mutations, present, n (%)    
 TET2 40 (41.7) 35 (38.9) .6995 
 ASXL1 26 (37.7) 36 (50.7) .1209 
 RAS 42 (17.4) 88 (36.5) <.0001 
 TP53 5 (5.2) 5 (5.6) .9164 
 RUNX1 15 (21.7) 13 (18.3) .6121 
Follow-up duration, median (range), mo 23.6 (0.0-191.9) 17.2 (0.0-147.0) <.0001 
Death, n (%) 183 (59.8) 249 (77.1) <.0001 
Survival time, median (95% CI), mo 33.8 (28.8-40.0) 21.1 (18.4-24.5) <.0001 
Duration to AML transformation, median (range), mo 22.0 (0.0-185.2) 15.2 (0.0-138.9) <.0001 
AML, n (%) 49 (16.0) 61 (18.9) .3432 
VariableMDS-CMMLMP-CMMLP*
Patients, N (%) 306 (48.6) 323 (51.4)  
Age, median (range), y 69.9 (31.2-91.1) 69.9 (24.8-87.6) .9559 
Age group, n (%), y    
 <60 61 (19.9) 55 (17.0) .4987 
 60-69 152 (49.7) 158 (48.9)  
 ≥70 93 (30.4) 110 (34.1)  
Sex, n (%)    
 Female 93 (30.4) 106 (32.8) .5133 
 Male 213 (69.6) 217 (67.2)  
WHO-2017, n (%)    
 CMML-0 122 (39.9) 92 (28.5) .0052 
 CMML-1 101 (33.0) 113 (35.0)  
 CMML-2 83 (27.1) 118 (36.5)  
WHO-2008, n (%)    
 CMML-1 223 (72.9) 205 (63.5) .0114 
 CMML-2 83 (27.1) 118 (36.5)  
PB parameters    
 WBC count, median (range), ×109/L 7.3 (0.8-12.9) 28.7 (13.0-223.1) <.0001 
 Hemoglobin concentration, median (range), g/dL 10.6 (5.9-16.0) 10.2 (5.1-16.4) .0905 
 Platelet count, median (range), ×109/L 88.5 (2.0-1554) 94.0 (5.0-912.0) .2705 
 Immature myeloid cells, median (minimum-maximum) 1.0 (0.0-34.0) 8.0 (0.0-50.0) <.0001 
 LDH, median (range), IU/L 537.0 (191-3400) 749.0 (142-11060) <.0001 
BM blast percentage, median (range) 5.5 (0.0-19.0) 6.0 (0.0-19.0) .7885 
MDAPS group, n (%)    
 High 47 (15.4) 57 (17.6) <.0001 
 Intermediate-2 98 (32.0) 186 (57.6)  
 Intermediate-1 110 (35.9) 66 (20.4)  
 Low 51 (16.7) 14 (4.3)  
CPSS group, n (%)    
 HIGH 16 (5.2) 49 (15.2) <.0001 
 INT-2 85 (27.8) 178 (55.1)  
 INT-1 90 (29.4) 96 (29.7)  
 Low 115 (37.6) 0 (0)  
CPSS cytogenetic risk groups, n (%) 
 High 58 (19.0) 50 (15.5) .0704 
 Intermediate 36 (11.8) 58 (18.0)  
 Low 212 (69.3) 215 (66.6)  
Tang cytogenetic risk groups, n (%) 
 High 36 (11.8) 36 (11.1) .5856 
 Intermediate 58 (19.0) 72 (22.3)  
 Low 212 (69.3) 215 (66.6)  
Mutations, present, n (%)    
 TET2 40 (41.7) 35 (38.9) .6995 
 ASXL1 26 (37.7) 36 (50.7) .1209 
 RAS 42 (17.4) 88 (36.5) <.0001 
 TP53 5 (5.2) 5 (5.6) .9164 
 RUNX1 15 (21.7) 13 (18.3) .6121 
Follow-up duration, median (range), mo 23.6 (0.0-191.9) 17.2 (0.0-147.0) <.0001 
Death, n (%) 183 (59.8) 249 (77.1) <.0001 
Survival time, median (95% CI), mo 33.8 (28.8-40.0) 21.1 (18.4-24.5) <.0001 
Duration to AML transformation, median (range), mo 22.0 (0.0-185.2) 15.2 (0.0-138.9) <.0001 
AML, n (%) 49 (16.0) 61 (18.9) .3432 

LDH, lactate dehydrogenase.

*

Kruskal-Wallis test and Wilcoxon rank-sum test for continuous factors and χ2 test for categorical factors as appropriate.

Full comparison conducted using treatment-naïve group (n = 499) showed comparable results with the following exception: P significant (.0251) in treatment-naïve group.

Sum of promyelocytes, myelocytes, and metamyelocytes in PB.

Close Modal

or Create an Account

Close Modal
Close Modal